Numinus Wellness Inc. announced the expansion of its psychedelics research facility with an additional lab and application for federal licensing, as it continues to broaden its services to support industry research and production while adding new revenue streams. As previously announced in a news release dated March 9, 2021, the expanded lab is housed in an existing the company’s-leased building adjacent to the current lab. Numinus Bioscience has submitted its application to Health Canada for its second dealer's license, for an additional 7,500 square feet. This facility will double the size of the company’s research footprint and is slated for completion in Summer 2022. The new space will be dedicated to the following services: bioanalytical testing; bioassay and in-vitro studies; research & development and formulation studies for several psychedelic compounds, including ketamine and LSD; and small batch manufacturing. The site design and application include a Level 7 security directive that permits expanded import, storage and distribution capabilities along with long-term stability studies for multiple products. The existing space will be dedicated to cultivating fungal starting materials such as Psilocybe mushrooms, and studying additional, currently under-researched, psychedelic botanicals. Already available and operating through its existing Health Canada licence and lab, the current site will expand its capabilities in extraction research, optimization and genomics for a variety of psychedelic materials. It will also continue to develop its verified Psilocybe tissue culture bank. These assets, along with provision of raw materials, finished dosages and regulatory support, will help industry stakeholders advance their initiatives in clinical and benchtop research.